Meeting
2011 ASCO Annual Meeting
Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
Authors
B. M. Dubray
CRLCC Henri Becquerel, Rouen, France
B. M. Dubray , V. Beckendorf , S. Guerif , E. Le Prise , A. Reynaud-Bougnoux , J. M. Hannoun Levi , T. D. Nguyen , C. Hennequin , J. Cretin , M. Fayolle-Campana , J. Lagrange , J. Bachaud , D. Azria , A. Grangirard , P. Pommier , J. Simon , V. Harter , M. Habibian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00104741
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4521)
Abstract #
4521
Poster Bd #
1
Abstract Disclosures